Novartis’ Scemblix meets primary endpoints in Phase III leukemia trial

Novartis’ Phase III trial investigating Scemblix (asciminib) as a first-line therapy in Philadelphia chromosome-positive chronic myeloid leukaemia (CML) has met its primary endpoints.